Expression profiles of miR-29c, miR-200b and miR-375 in tumour
and tumour-adjacent tissues of head and neck cancers

J 2016

Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers

HUDCOVÁ, Kristýna, Martina RAUDENSKÁ, Jaromír GUMULEC, Hana BINKOVA, Zuzana HORAKOVA et. al.

Basic information

Original name

Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers

Authors

HUDCOVÁ, Kristýna (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Hana BINKOVA (203 Czech Republic), Zuzana HORAKOVA (203 Czech Republic), Rom KOSTRICA (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Vojtech ADAM (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

Tumor Biology, Dordrecht, Springer, 2016, 1010-4283

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.650

RIV identification code

RIV/00216224:14110/16:00088428

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s13277-016-5147-2

UT WoS

000387075400102

Keywords in English

Head and neck neoplasms; Carcinoma; squamous cell of head and neck; MicroRNAs; Biomarkers; tumour; Survival; Proportional hazards models

Abstract

V originále

Altered expression of microRNAs (miRNAs) has been shown in many types of malignancies including the head and neck squamous cell carcinoma (HNSCC). Although there are many new and innovative approaches in the treatment of HNSCC, a clear marker of this disease is still missing. Three candidate miRNAs (miR-29c-3p, miR-200b-5p and miR-375-3p) were studied in connection with HNSCC using quantitative real-time PCR expression levels in 42 tissue samples of HNSCC patients and histologically normal tumour-adjacent tissue samples of these patients. Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression (sensitivity 87.5 %, specificity 65 %). Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity. Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with higher tumour grade. Consequently, survival analysis was performed. Lower expression of hsa-miR-29c-3p in tumour-adjacent tissue was associated with worse overall and disease-specific survivals. Lower expression of miR-29c-3p in tumourous tissue was associated with worse relapse-free survival. hsa-miR-375-3p seems to be a relatively promising diagnostic marker in HNSCC but is not suitable for prognosis of patients. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in HNSCC progress (significant decrease of hsa-miR-200b-5p expression in tumour-adjacent tissue of patients with node positivity and low expression of hsa-miR-29c-3p in HNSCC tumour-adjacent tissue associated with worse prognosis).

Links

GA16-12454S, research and development project

Name: Charakterizace a modifikace komplexní odpovědi buněk nádorů hlavy a krku na různá záření - krok kupředu ke kombinované personalizované (radio)terapii

Investor: Czech Science Foundation

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

MUNI/A/1365/2015, interní kód MU

Name: Kardiovaskulární systém: od modelu přes terapii k prevenci (Acronym: KAMOTEPRE)

Investor: Masaryk University, Category A

MUNI/A/1426/2015, interní kód MU

Name: Genetická a epigenetická patofyziologie vybraných stavů (Acronym: Genetika a epigenetika)

Investor: Masaryk University, Category A

NV16-29835A, research and development project

Name: Molekulárně-genetické markery predikce účinnosti radioterapie u nádorů hlavy a krku

Citovat

HUDCOVÁ, Kristýna, Martina RAUDENSKÁ, Jaromír GUMULEC, Hana BINKOVA, Zuzana HORAKOVA, Rom KOSTRICA, Petr BABULA, Vojtech ADAM and Michal MASAŘÍK. Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. Tumor Biology. Dordrecht: Springer, 2016, vol. 37, No 9, p. 12627-12633. ISSN 1010-4283. Available from: https://dx.doi.org/10.1007/s13277-016-5147-2.

@article{1364173,
   author = {Hudcová, Kristýna and Raudenská, Martina and Gumulec, Jaromír and Binkova, Hana and Horakova, Zuzana and Kostrica, Rom and Babula, Petr and Adam, Vojtech and Masařík, Michal},
   article_location = {Dordrecht},
   article_number = {9},
   doi = {http://dx.doi.org/10.1007/s13277-016-5147-2},
   keywords = {Head and neck neoplasms; Carcinoma; squamous cell of head and neck; MicroRNAs; Biomarkers; tumour; Survival; Proportional hazards models},
   language = {eng},
   issn = {1010-4283},
   journal = {Tumor Biology},
   title = {Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers},
   volume = {37},
   year = {2016}
}

TY  - JOUR
ID  - 1364173
AU  - Hudcová, Kristýna - Raudenská, Martina - Gumulec, Jaromír - Binkova, Hana - Horakova, Zuzana - Kostrica, Rom - Babula, Petr - Adam, Vojtech - Masařík, Michal
PY  - 2016
TI  - Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers
JF  - Tumor Biology
VL  - 37
IS  - 9
SP  - 12627-12633
EP  - 12627-12633
PB  - Springer
SN  - 10104283
KW  - Head and neck neoplasms
KW  - Carcinoma
KW  - squamous cell of head and neck
KW  - MicroRNAs
KW  - Biomarkers
KW  - tumour
KW  - Survival
KW  - Proportional hazards models
N2  - Altered expression of microRNAs (miRNAs) has been shown in many types of malignancies including the head and neck squamous cell carcinoma (HNSCC). Although there are many new and innovative approaches in the treatment of HNSCC, a clear marker of this disease is still missing. Three candidate miRNAs (miR-29c-3p, miR-200b-5p and miR-375-3p) were studied in connection with HNSCC using quantitative real-time PCR expression levels in 42 tissue samples of HNSCC patients and histologically normal tumour-adjacent tissue samples of these patients. Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression (sensitivity 87.5 %, specificity 65 %). Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity. Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with higher tumour grade. Consequently, survival analysis was performed. Lower expression of hsa-miR-29c-3p in tumour-adjacent tissue was associated with worse overall and disease-specific survivals. Lower expression of miR-29c-3p in tumourous tissue was associated with worse relapse-free survival. hsa-miR-375-3p seems to be a relatively promising diagnostic marker in HNSCC but is not suitable for prognosis of patients. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in HNSCC progress (significant decrease of hsa-miR-200b-5p expression in tumour-adjacent tissue of patients with node positivity and low expression of hsa-miR-29c-3p in HNSCC tumour-adjacent tissue associated with worse prognosis).
ER  -

HUDCOVÁ, Kristýna, Martina RAUDENSKÁ, Jaromír GUMULEC, Hana BINKOVA, Zuzana HORAKOVA, Rom KOSTRICA, Petr BABULA, Vojtech ADAM and Michal MASAŘÍK. Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. \textit{Tumor Biology}. Dordrecht: Springer, 2016, vol.~37, No~9, p.~12627-12633. ISSN~1010-4283. Available from: https://dx.doi.org/10.1007/s13277-016-5147-2.

Detailed Information on Publication Record